Demant A/S/€DEMANT
Demant shares fall as investors reassess limited upside after the sharp 2026 rally, with Jefferies’ downgrade to Hold and analyst concerns about valuation weighing on sentiment.
6 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Demant A/S
Demant A/S is a company specializing in hearing healthcare solutions. It operates in the medical technology industry, providing hearing aids, audiometric equipment, and hearing implants. The company also offers personal communication solutions and hearing care services through its retail network. Founded in 1904 and headquartered in Smørum, Denmark, Demant has a significant presence in Europe, North America, and other regions, serving users worldwide. The company's strategic positioning is strengthened by its focus on R&D and innovation, which supports its diverse product portfolio and ability to meet various customer needs in the hearing health market.
- Ticker
- €DEMANT
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 26,616
- Headquarters
- Smørum, Denmark
- Website
- www.demant.com
Demant A/S Metrics
BasicAdvanced
€10B
48.50
€1.02
0.76
-
Price and volume
Market cap
€10B
Beta
0.76
52-week high
€49.68
52-week low
€23.50
Average daily volume
351K
Financial strength
Current ratio
0.821
Quick ratio
0.531
Long term debt to equity
1.16
Total debt to equity
1.792
Interest coverage (TTM)
7.82%
Profitability
EBITDA (TTM)
665.104
Gross margin (TTM)
76.25%
Net profit margin (TTM)
6.55%
Operating margin (TTM)
17.20%
Effective tax rate (TTM)
23.76%
Revenue per employee (TTM)
€124,400
Management effectiveness
Return on assets (TTM)
7.29%
Return on equity (TTM)
23.30%
Valuation
Price to earnings (TTM)
48.505
Price to revenue (TTM)
3.176
Price to book
6.95
Price to tangible book (TTM)
-8.28
Price to free cash flow (TTM)
25.201
Free cash flow yield (TTM)
3.97%
Free cash flow per share (TTM)
1.967
Growth
Revenue change (TTM)
9.06%
Earnings per share change (TTM)
-29.26%
3-year revenue growth (CAGR)
5.62%
10-year revenue growth (CAGR)
7.98%
3-year earnings per share growth (CAGR)
1.92%
10-year earnings per share growth (CAGR)
3.98%
Bulls say / Bears say
Hearing Aids grew 17% organically in Q3, with Oticon Reveal driving sales above the market and helping Demant gain value share. That builds on the earlier momentum from Oticon Zeal. (Demant A/S)
Demant raised its 2026 outlook to 7–8% organic growth and DKK 4.7–5.0 billion EBIT before special items. Strong sales have also improved operating leverage and cash flow, allowing the company to resume share buy-backs. (Demant A/S)
Growth is not limited to hearing aid sales: Hearing Care delivered 6% organic growth in Q3, with KIND lifting acquisitive growth, while Diagnostics grew 4%. That gives Demant several sources of revenue growth across hearing healthcare. (Demant A/S)
Management’s outlook implies organic growth of about 5% in Q4, down from 11% in Q3. It cited tougher comparisons, a normalising market and uncertainty about competitors’ product launches, so the recent surge may not be sustained. (Investing.com)
The KIND acquisition and cost-saving programme bring significant integration and restructuring costs: Demant expects DKK 400 million of special items in 2026 and another DKK 100 million in 2027. Net debt was DKK 17.95 billion and gearing stood at 3.0 at the end of June, above its 2.0–2.5 target range. (Nasdaq)
Foreign exchange is forecast to reduce 2026 EBIT before special items by around DKK 125 million compared with 2025. This is a meaningful headwind even as the company raises its earnings outlook. (Demant A/S)
Data summarised monthly by Lightyear AI. Last updated on 12 Nov 2026.
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.